Tirzepatide vs Semaglutide: Tirzepatide Lost 20.2% to Semaglutide’s 13.7% in the Only Head-to-Head Obesity Trial. Semaglutide Has the Heart Trial Tirzepatide Doesn’t.

Tirzepatide has the bigger number: 20.2% against 13.7%, in one open-label, Lilly-funded trial. Semaglutide has the bigger trial: 17,604 people and a fifth fewer heart attacks and strokes. Which matters depends on what you are trying to lose.








